Santen Announces Change of Major Shareholder
Filed with TSE · · 2 pages · English
Santen Pharmaceutical Co., Ltd. on 6ix
Earlier from Santen Pharmaceutical
- Notice Regarding the Petition for Commencement of Bankruptcy Proceedings of a Consolidated Subsidiary
- Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
- New Drug Application Filing Accepted for Review in China for STN1012700 (Atropine Sulfate Ophthalmic Solution 0.025%), an Ophthalmic Solution to Slow the Progression of Myopia
- Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 (IFRS)
- Santen Pharmaceutical: China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Eyedrops Products in the Chinese Mainland
Later from Santen Pharmaceutical
- Santen Announces Share Buyback
- Summary of Consolidated Financial Results for the Six Months Ended September 30, 2026 (IFRS)
Follow Santen Pharmaceutical into a list and get an email when it puts out news.
Follow Santen Pharmaceutical